.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..: "evidence for decreased calcitonin gene-related peptide (cgrp) receptors and compromised responsiveness to cgrp of fetoplacental vessels in preeclamptic pregnancies.".derek and his wife, michelle, have three boys, ages 11, 16 and 17..